Insight Molecular Diagnostics Inc. IMDX 深 沪
等待开盘 03-26 09:30:00 美东时间
4.10
+0.100
+2.50%
华盛通- 最 高4.45
- 今 开4.12
- 成交量 14.85万股
- 最 低 3.69
- 昨 收 4.00
- 总市值 1.32亿
- 52周最高 8.51
- 市盈率 静 --
- 换手率 0.46%
- 52周最低 2.33
- 委 比 62.08%
- 总股本 3214.69万
- 历史最高 204.80
- 量 比 0.83
- 振 幅 19.00%
- 历史最低 1.922
- 每 手 1
- 风险率 1.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Insight Molecular Diagnostics publishes financial calendar update
Insight Molecular Diagnostics publishes financial calendar update iMDx will report fourth-quarter financial results after the market closes on March 26, 2026. A live Zoom webinar to discuss the results is scheduled for March 26, 2026 at 2:00 pm PT / 5:00 pm ET, with registration at iMDx Q4 2025 Earn
03-20 20:01
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc. highlighted a new peer-reviewed study demonstrating the potential superiority of its GraftAssure assay technology, featuring 249 biopsy-matched kidney transplant patients. The proprietary Combination Model (CM)-score outperformed percentage-only measures of dd-cfDNA, showing strong correlation with rejection indices, including Antibody-mediated Rejection (AMR) and T-Cell Mediated Rejection (TCMR). The study, con...
03-13 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Insight Molecular Diagnostics ( ($IMDX) ) has issued an update. On February 20,...
02-27 05:42
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
Insight Molecular Diagnostics Raises Capital to Advance Transplant R&D
Insight Molecular Diagnostics ( ($IMDX) ) has provided an update. Insight Molec...
02-13 06:51
Insight Molecular Diagnostics Provides Updated Investor Presentation Materials
The latest announcement is out from Insight Molecular Diagnostics ( ($IMDX) ). ...
02-11 21:32
Insight Molecular Diagnostics Commences ~$26M Offering Of 4.526M Common Shares At $5.75/Share
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate
02-11 21:01
iMDx Announces $26.0 Million Registered Direct Offering
<p>Insight Molecular Diagnostics Inc. announced the sale of 4.5 million shares at $5.75 each, raising approximately $26 million. The funds will support research and development, particularly expanding GraftAssure to heart transplant testing. The offering is under a shelf registration and Lake Street Capital Markets acted as agent. A significant shareholder, Bio-Rad, also participated. The company aims to use proceeds for general corporate purpose...
02-11 13:00
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring
Insight Molecular Diagnostics Inc. (iMDx) congratulated the STAR working group for its position paper in the *American Journal of Transplantation*, which emphasizes the importance of decentralized dd-cfDNA testing for transplant patients. The paper highlights the need for standardized, high-quality testing to support multicenter studies and real-world evidence generation, aligning with iMDx's strategy to decentralize organ health testing. iMDx CE...
01-13 14:00
